U.S. markets open in 19 minutes
  • S&P Futures

    4,131.25
    +24.25 (+0.59%)
     
  • Dow Futures

    34,070.00
    +132.00 (+0.39%)
     
  • Nasdaq Futures

    13,232.50
    +132.25 (+1.01%)
     
  • Russell 2000 Futures

    2,184.30
    +15.70 (+0.72%)
     
  • Crude Oil

    64.41
    +0.59 (+0.92%)
     
  • Gold

    1,836.50
    +12.50 (+0.69%)
     
  • Silver

    27.40
    +0.34 (+1.26%)
     
  • EUR/USD

    1.2136
    +0.0051 (+0.42%)
     
  • 10-Yr Bond

    1.6370
    -0.0310 (-1.86%)
     
  • Vix

    21.39
    -6.20 (-22.47%)
     
  • GBP/USD

    1.4084
    +0.0032 (+0.23%)
     
  • USD/JPY

    109.3660
    -0.0680 (-0.06%)
     
  • BTC-USD

    50,239.05
    -76.15 (-0.15%)
     
  • CMC Crypto 200

    1,395.97
    +8.06 (+0.58%)
     
  • FTSE 100

    7,015.20
    +51.87 (+0.74%)
     
  • Nikkei 225

    28,084.47
    +636.46 (+2.32%)
     

AtriCure to Announce First Quarter 2021 Financial Results

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2021 financial results on Tuesday, April 27, 2021.

AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, April 27, 2021 to discuss its first quarter 2021 financial results. The call may be accessed through an operator by calling (844) 884-9951 for domestic callers and (661) 378-9661 for international callers using conference ID number 3349395. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure’s corporate website at ir.atricure.com. A replay of the presentation will be available for 90 days following the presentation.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210406005179/en/

Contacts

Angie Wirick
AtriCure, Inc.
Chief Financial Officer
(513) 755-5334
awirick@atricure.com

Lynn Pieper Lewis
Gilmartin Group
Investor Relations
(415) 937-5402
lynn@gilmartinir.com